Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GI-102 consolidation after anti-CD19 CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma (CARNATION)
KCT0009580Phase 2Recruiting
- Sponsor
- GI Innovation
- Start
- Dec 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GI-101A in diffuse large B-cell lymphoma (DLBCL), sponsored by GI Innovation. Started Dec 2024; status: recruiting.
02
Drugs
GI-101A
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on KCT0009580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009580.